NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis

Amphastar Pharmaceuticals, Inc. (AMPH) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AMPH

$26.20

+$0.26 (+1.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMPH with… →

AMPH Key Statistics

As of Oct 21, 2026
Trading
Open
$25.69
Previous Close
$25.94
Day's Range
25.51–26.35
52-Week Range
16.65–29.52
Volume
390.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.90
Valuation
Market Cap
$1.11B
P/E Ratio
15.50
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
8.23
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.53
EPS (ttm)Profit attributable to each share over the last twelve months.
1.69
Financials (FY)
Revenue (FY)
$719.89M−1.65%
Net Income (FY)
$98.09M−38.51%
Profit marginThe share of revenue left as profit after all costs and taxes.
10.76%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.54M
1-Year Return
+8.00%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
466.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AMPH closed at $26.20, +8.00% over 1 year.

Amphastar Pharmaceuticals, Inc. (AMPH) has a market capitalization of $1.11B.

In fiscal 2025, AMPH reported revenue of $719.89M.

AMPH Stock Return by Calendar Year

Amphastar Pharmaceuticals, Inc. (AMPH) 10-year return: what $10,000 became

1 year
$10,000 $10,800
+8.00%
5 years
$10,000 $13,603
+36.03%
10 years
$10,000 $14,094
+40.94%

If you had invested $10,000 in Amphastar Pharmaceuticals, Inc. (AMPH) 10 years ago, at the close on October 21, 2016, it would have been worth $14,094 at the close on October 21, 2026: +40.94% in total, +3.49% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.17%
2025−27.88%
2024−39.97%
2023+120.74%
2022+20.31%
2021+15.81%
2020+4.25%
2019−3.07%
2018+3.43%
2017+4.45%
2016 (partial year)+14.98%

As of October 21, 2026.

AMPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$719.89M$98.09M13.6%
2024$731.97M$159.52M21.8%
2023$644.40M$137.55M21.3%
2022$498.99M$91.39M18.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$719.89M$356.06M$140.40M$98.09M13.6%
2024$731.97M$373.86M$205.42M$159.52M21.8%
2023$644.40M$351.12M$196.99M$137.55M21.3%
2022$498.99M$248.86M$107.50M$91.39M18.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AMPH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricAMPHDrug Manufacturers - Specialty & Generic medianvs median
P/E15.5020.3124% below
P/S ratio1.532.1027% below
Profit margin10.76%−8.14%18.9 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amphastar Pharmaceuticals, Inc. (AMPH) carries a market capitalisation of $1.11B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 1,976.

The 52-week range on file runs from $16.65 to $29.52. The most recent close on file for AMPH is $26.20, dated October 21, 2026. That is +$0.26 (+1.00%) against the previous close. The latest close sits 57.36% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $719.89M. That is −1.65% against the prior fiscal year, when revenue was $731.97M. The same year closed with net income of $98.09M. That is −38.51% against the prior fiscal year. Profit margin runs at 10.76%. That is 18.9 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 1.69.

Across the 4 fiscal years on file, revenue moves from $498.99M in 2022 to $719.89M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

AMPH trades at a trailing price-to-earnings ratio of 15.5. That is 23.7% below the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 8.23. Measured against sales, the shares trade at 1.53 times revenue. On price-to-sales that is 27.3% below the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the total return is +8.00%. Measured over 10 years, that is +3.49% a year compounded. The reported beta is 0.9. Daily returns over the trailing 10 years annualize to a volatility of 42.53%.

Growth & Income

No dividend is on file for AMPH.

Across the complete calendar years on file, 2023 returned +120.74% and 2024 returned −39.97%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the total return is −2.17%.

Peer Comparison

Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amphastar Pharmaceuticals, Inc. AMPH $1.11B 15.5
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Amphastar Pharmaceuticals, Inc. trades at a P/E of 15.5.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Visit website →